Stocks
Amgen Sees Strong Growth Prospects as Kimelman & Baird Invests $5.157 Million
Kimelman & Baird LLC has acquired a new stake in Amgen Inc. (NASDAQ: AMGN), purchasing 14,240 shares of the medical research company's stock during the second quarter.
The acquisition was valued at approximately $5,157,000 and represents a significant investment in the company's future growth prospects.
Amgen has seen strong financial performance recently, exceeding analyst expectations for both earnings and revenue in its latest reported quarter. The company's revenue increased year over year, driven by the success of its pipeline products.